Skip to main content

Table 2 Changes in the WOMAC score during the treatment in PP populationa

From: Treatment of knee osteoarthritis with a new formulation of a fixed-dose combination of glucosamine sulfate and bovine chondroitin: a multicenter, randomized, single-blind, non-inferiority clinical trial

WOMAC GS/ CS
(N = 209)
RP
(N = 223)
Difference between the treatments CI (95%)
Absolute change in score of WOMAC “pain” subscale, mm, mean (se)
Week 6 - 18.2 (1.7) - 20.2 (1.72) 1.98 (2) (− 1.95; 5.9)
Week 12 - 23.3 (1.7) - 24.7 (1.7) 1.3 (2) (− 2.6; 5.3)
Week 24 - 32.8 (1.8) −33.3 (1.7) 0.54 (2) (− 3.5; 4.5)
Absolute change in score of WOMAC “stiffness” subscale, mm, mean (se)
Week 6 - 15.4 (2) - 17 (2) 1.6 (2.3) (− 3; 6.1)
Week 12 - 19.1 (2) - 22.5 (2) 3.4 (2.3) (− 1.1; 8)
Week 24 - 28.6 (2) - 30.1 (2) 1.4 (2.4) (− 3.2; 6.1)
Absolute change in score of WOMAC “function” subscale, mm, mean (se)
Week 6 - 14.2 (1.7) - 15.1 (1.7) 0.9 (2) (− 2.94; 4.78)
Week 12 - 19.6 (1.7) - 21.4 (1.7) 1.8 (2) (−  2.1; 5.7)
Week 24 - 28.9 (1.8) - 29.5 (1.7) 0.6 (2) (− 3.3; 4.5)
Absolute change in WOMAC total score, mm, mean (se)
Week 6 - 48.1 (5.1) - 52.83 (5) 4.8 (5.8) (− 6.6; 16.1)
Week 12 - 62.3 (5.1) - 69.1 (5) 6.9 (5.8) (− 4.6; 18.3)
Week 24 - 90.6 (5.1) - 93.4 (5.1) 2.9 (5.9) (−8.7; 14.4)
  1. aEstimates of the mixed model for repeated measures adjusted per baseline score and site. CI (95%) two-sided confidence interval for change mean, with confidence coefficient of 95%, GS/CS glucosamine sulfate/ chondroitin sulfate, PP per protocol, RP Reference Product, se standard estimate, WOMAC Western Ontario and McMaster Universities questionnaire (score normalized at the scale from 0 to 100 mm)